This little-known biopharmaceutical outfit has signed not just one but seven partnership pacts with Big Pharmas to help develop some of its products. Micromet’s No. 1 appeal: It’s developing novel antibody-based drugs to treat cancer, inflammatory and autoimmune diseases.
Continue reading Inside Wall Street: Why Micromet Is a Small Biotech With Big Potential
Inside Wall Street: Why Micromet Is a Small Biotech With Big Potential originally appeared on DailyFinance on Mon, 27 Dec 2010 07:30:00.
Filed Under: Company News, Columns, Health Care, Stock Picks, Insurance